{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:41:19Z","timestamp":1790606479723,"version":"4.1.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1097\/hjh.0b013e3282f3ef5e","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:03:32Z","timestamp":1236269012000},"page":"622-629","source":"Crossref","is-referenced-by-count":80,"title":["Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"26","author":[{"given":"Craig I","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210208","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/00002018-200124100-00002","article-title":"Antihypertensive therapy and cancer risk","volume":"24","author":"Feldemen","year":"2001","journal-title":"Drug Saf"},{"key":"R2-2-20210208","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(75)91826-7","article-title":"High blood pressure; a risk factor for cancer mortality?","volume":"1","author":"Dyer","year":"1975","journal-title":"Lancet"},{"key":"R3-2-20210208","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oxfordjournals.aje.a113105","article-title":"High blood pressure and 17-year cancer mortality in the Western Electric Health Study","volume":"113","author":"Raynor","year":"1981","journal-title":"Am J Epidemiol"},{"key":"R4-2-20210208","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/1097-0142(19870401)59:7<1386::AID-CNCR2820590726>3.0.CO;2-B","article-title":"Cancer incidence in hypertensives","volume":"59","author":"Buck","year":"1987","journal-title":"Cancer"},{"key":"R5-2-20210208","first-page":"63","article-title":"Elevated systolic blood pressure as a predictor of long-term cancer mortality: analysis by site and histologic subtype in 10,000 middle age and elderly-men","volume":"77","author":"Goldbourt","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"R6-2-20210208","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ije\/25.1.22","article-title":"Blood pressure and cancer in middle-aged British men","volume":"25","author":"Wannamethee","year":"1996","journal-title":"Int J Epidemiol"},{"key":"R7-2-20210208","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0021-9681(83)90145-5","article-title":"The impact of elevated blood pressure upon 10-year mortality among Japanese men in Howaii: the Honolulu Heart Program","volume":"36","author":"Yano","year":"1983","journal-title":"J Chronic Dis"},{"key":"R8-2-20210208","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/bmj.306.6878.609","article-title":"Incidence of and mortality from cancer in hypertensive patients","volume":"306","author":"Hole","year":"1993","journal-title":"BMJ"},{"key":"R9-2-20210208","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0002-9343(02)01049-5","article-title":"Is there an association between hypertension and cancer mortality?","volume":"112","author":"Grossman","year":"2002","journal-title":"Am J Med"},{"key":"R10-2-20210208","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","article-title":"Calcium channel blockers and risk of cancer","volume":"349","author":"Pahor","year":"1997","journal-title":"Lancet"},{"key":"R11-2-20210208","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0895-7061(96)00186-0","article-title":"Do calcium-channel blockers increase the risk of cancer?","volume":"9","author":"Pahor","year":"1996","journal-title":"Am J Hypertens"},{"key":"R12-2-20210208","first-page":"439","article-title":"Case-control study in colon cancer regarding previous diseases and drug intake","volume":"8","author":"Hardell","year":"1995","journal-title":"Int J Oncol"},{"key":"R13-2-20210208","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6","article-title":"Use of calcium channel blockers and breast carcinoma risk in postmenopausal women","volume":"80","author":"Fitzpatrick","year":"1997","journal-title":"Cancer"},{"key":"R14-2-20210208","first-page":"351","article-title":"Cigarette cmoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma","volume":"77","author":"Yu","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"R15-2-20210208","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00053150","article-title":"Risk factors for renal cell carcinoma: results of a population-based case-control study","volume":"4","author":"Kreiger","year":"1993","journal-title":"Cancer Causes Control"},{"key":"R16-2-20210208","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/oxfordjournals.aje.a117328","article-title":"Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer","volume":"140","author":"Weinmann","year":"1994","journal-title":"Am J Epidemiol"},{"key":"R17-2-20210208","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","article-title":"Hypertension, diuretics and breast cancer risk","volume":"20","author":"Largent","year":"2006","journal-title":"J Hum Hypertens"},{"key":"R18-2-20210208","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/157488607780598296","article-title":"Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis","volume":"2","author":"Carrao","year":"2007","journal-title":"Current Drug Safety"},{"key":"R19-2-20210208","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","article-title":"Antihypertensive therapy and the risk of malignancies","volume":"22","author":"Grossman","year":"2001","journal-title":"Eur Heart J"},{"key":"R20-2-20210208","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0959-8049(02)00157-0","article-title":"Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study","volume":"39","author":"Beiderbeck-Noll","year":"2003","journal-title":"Eur J Cancer"},{"key":"R21-2-20210208","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/j.1875-9114.1997.tb03084.x","article-title":"A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil","volume":"17","author":"Dong","year":"1997","journal-title":"Pharmacotherapy"},{"key":"R22-2-20210208","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","article-title":"Cancer risk in users of calcium channel blockers","volume":"29","author":"Olsen","year":"1997","journal-title":"Hypertension"},{"key":"R23-2-20210208","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004872-199816010-00017","article-title":"Cancer risk of hypertensive patients taking calcium channel antagonists","volume":"16","author":"Hole","year":"1998","journal-title":"J Hypertens"},{"key":"R24-2-20210208","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2003::AID-CNCR17>3.0.CO;2-3","article-title":"Calcium channel blockers, cancer incidence, and cancer mortality in a cofort of U.S. women: the Nurses' Health Study","volume":"83","author":"Michels","year":"1998","journal-title":"Cancer"},{"key":"R25-2-20210208","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/ije\/23.5.923","article-title":"Risk farcors for renal cell carcinoma in Denmark: role of medication and medical history","volume":"23","author":"Mellemgaard","year":"1994","journal-title":"Int J Epidemiol"},{"key":"R26-2-20210208","first-page":"327","article-title":"Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension","volume":"4","author":"Chow","year":"1995","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R27-2-20210208","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.2910630212","article-title":"International renal-cell cancer study. VIII. Role of diuretics, other antihypertensive medications and hypertension","volume":"63","author":"McLaughlin","year":"1995","journal-title":"Int J Cancer"},{"key":"R28-2-20210208","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","article-title":"Antihypertensive drug use and the risk of prostate cancer","volume":"15","author":"Perron","year":"2004","journal-title":"Cancer Causes Control"},{"key":"R29-2-20210208","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/cncr.11663","article-title":"Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65\u201379 years","volume":"98","author":"Li","year":"2003","journal-title":"Cancer"},{"key":"R30-2-20210208","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00146885","article-title":"Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obestity, and hormonal factors","volume":"3","author":"McCredie","year":"1992","journal-title":"Cancer Causes Control"},{"key":"R31-2-20210208","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"R32-2-20210208","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0140-6736(05)63025-5","article-title":"Inhibition of angiogenesis in Kaposi's sarcoma by captopril","volume":"349","author":"Vogt","year":"1997","journal-title":"Lancet"},{"key":"R33-2-20210208","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","article-title":"Association between captopril, other antihypertensive drugs and risk of prostate cancer","volume":"58","author":"Ronquist","year":"2004","journal-title":"Prostate"},{"key":"R34-2-20210208","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer"},{"key":"R35-2-20210208","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-005-9091-x","article-title":"A cohort study of antihypertensive medication use and breast cancer among Danish women","volume":"97","author":"Fryzek","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"R36-2-20210208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pros.20486","article-title":"Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer","volume":"67","author":"Kosaka","year":"2007","journal-title":"Prostate"},{"key":"R37-2-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clin Trials"},{"key":"R38-2-20210208","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-Analysis in clinical trials","volume":"7","author":"Dersimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R39-2-20210208","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.1974.03230420021019","article-title":"Effect of antihypertensive treatment on stroke recurrence.","volume":"229","year":"1974","journal-title":"JAMA"},{"key":"R40-2-20210208","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.293.6555.1145","article-title":"Randomized trial of treatment of hypertension in elderly patients in primary care","volume":"293","author":"Coope","year":"1986","journal-title":"BMJ"},{"key":"R41-2-20210208","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004872-199103000-00005","article-title":"Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly (EWPHE)","volume":"9","author":"Fletcher","year":"1991","journal-title":"J Hypertens"},{"key":"R42-2-20210208","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"R43-2-20210208","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"R44-2-20210208","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.1996.03540100029024","article-title":"Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial","volume":"276","author":"Borhani","year":"1996","journal-title":"JAMA"},{"key":"R45-2-20210208","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/00004872-199610000-00013","article-title":"Sanghai Trial Of Nifedipine in the Elderly (STONE)","volume":"14","author":"Gong","year":"1996","journal-title":"J Hypertens"},{"key":"R46-2-20210208","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"R47-2-20210208","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R48-2-20210208","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti","year":"1998","journal-title":"Diabetes Care"},{"key":"R49-2-20210208","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"N Engl J Med"},{"key":"R50-2-20210208","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"R51-2-20210208","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1369::AID-CNCR21>3.0.CO;2-5","article-title":"Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem","volume":"85","author":"Kanamasa","year":"1999","journal-title":"Cancer"},{"key":"R52-2-20210208","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9149(99)00113-7","article-title":"Verapamil and risk of cancer in patients with coronary artery disease","volume":"83","author":"Sajadieh","year":"1999","journal-title":"Am J Cardiol"},{"key":"R53-2-20210208","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.HYP.34.5.1129","article-title":"Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives.","volume":"34","year":"1999","journal-title":"Hypertension"},{"key":"R54-2-20210208","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","article-title":"Effect of amlodipine on the progresson of atherosclerosis and the occurrence of clinical events","volume":"102","author":"Pitt","year":"2000","journal-title":"Circulation"},{"key":"R55-2-20210208","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"R56-2-20210208","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","article-title":"Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin\/Enalapril Coronary Atherosclerosis Trial (SCAT)","volume":"102","author":"Teo","year":"2000","journal-title":"Circulation"},{"key":"R57-2-20210208","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R58-2-20210208","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R59-2-20210208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol","volume":"359","author":"Dahlor","year":"2002","journal-title":"Lancet"},{"key":"R60-2-20210208","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"R61-2-20210208","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"R62-2-20210208","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"R63-2-20210208","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.STR.0000147041.00840.59","article-title":"Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering pravastatin on progression of asymptomatic carotid atherosclerosis. Principal results of PHYLLIS: a randomized double-blind trial","volume":"35","author":"Zanchetti","year":"2004","journal-title":"Stroke"},{"key":"R64-2-20210208","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","article-title":"The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients","volume":"23","author":"Liu","year":"2005","journal-title":"J Hypertens"},{"key":"R65-2-20210208","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"Feasibility of treating prehypertension with an angiotensin-receptor blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N Engl J Med"},{"key":"R66-2-20210208","doi-asserted-by":"crossref","first-page":"445.e7","DOI":"10.1016\/j.ahj.2006.12.005","article-title":"Effects of zofenopril on myocardial ischemia in postmyocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study","volume":"153","author":"Borghi","year":"2007","journal-title":"Am Heart J"},{"key":"R67-2-20210208","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"289","author":"Chobian","year":"2003","journal-title":"JAMA"},{"key":"R68-2-20210208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1006233521325","article-title":"Mechanism of captopril toxicity to a human mamary ductal carcinoma cell line in the presence of copper","volume":"55","author":"Small","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"R71-2-20210208","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2337\/diacare.28.9.2261","article-title":"The impact of ACE inhibitors and angiotensin II receptor blockers on the development of type-II diabetes","volume":"28","author":"Gillespie","year":"2005","journal-title":"Diabetes Care"},{"key":"R72-2-20210208","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk. A meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-200804000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T03:28:48Z","timestamp":1710127728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-200804000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3282f3ef5e","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}